Lexeo Therapeutics, Inc.

NasdaqGM:LXEO Stock Report

Market Cap: US$330.6m

Lexeo Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:LXEO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 May 26SellUS$16,927R. TownsendIndividual3,342US$5.06
18 May 26SellUS$6,606Jose OteroIndividual1,302US$5.07
18 Feb 26SellUS$64,924R. TownsendIndividual10,173US$6.38
18 Feb 26SellUS$19,294Jose OteroIndividual3,016US$6.40
18 Nov 25SellUS$5,089Jenny RobertsonIndividual549US$9.27
18 Nov 25SellUS$3,578Sandi TaiIndividual386US$9.27
18 Nov 25SellUS$5,701Eric AdlerIndividual615US$9.27
18 Nov 25SellUS$10,447R. TownsendIndividual1,127US$9.27
18 Nov 25SellUS$6,684Jose OteroIndividual721US$9.27
17 Oct 25SellUS$117,436R. TownsendIndividual13,133US$9.56
17 Oct 25SellUS$30,242Eric AdlerIndividual3,382US$9.56
17 Oct 25SellUS$18,913Jose OteroIndividual2,115US$9.56
17 Oct 25SellUS$31,530Jenny RobertsonIndividual3,526US$9.56
17 Oct 25SellUS$34,767Sandi TaiIndividual3,888US$9.56
18 Aug 25SellUS$1,783Sandi TaiIndividual382US$4.67
18 Aug 25SellUS$5,205R. TownsendIndividual1,115US$4.67
18 Aug 25SellUS$2,838Eric AdlerIndividual608US$4.67
18 Aug 25SellUS$2,530Jenny RobertsonIndividual542US$4.67
18 Aug 25SellUS$13,294Jose OteroIndividual2,848US$4.67

Insider Trading Volume

Insider Buying: LXEO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of LXEO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders206,5170.227%
VC/PE Firms9,424,72510.4%
Hedge Funds21,384,12323.5%
Institutions59,848,00165.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 43.2%.

Top Shareholders

Top 25 shareholders own 98.43% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.88%
Paradigm Biocapital Advisors LP
6,184,134US$26.0m29.8%0.65%
7.23%
Suvretta Capital Management, LLC
5,674,778US$23.9m354%0.61%
6.51%
BlackRock, Inc.
5,110,871US$21.5m4.14%no data
6.43%
Affinity Asset Advisors, LLC
5,050,211US$21.3m57.8%1.46%
6.37%
RA Capital Management, L.P.
5,000,000US$21.0m0%0.3%
6.34%
Janus Henderson Group plc
4,976,429US$21.0m-9.68%0.01%
5.7%
Vestal Point Capital, LP
4,475,000US$18.8m0%0.56%
5.64%
Frazier Life Sciences Management, LP
4,424,725US$18.6m0%0.52%
4.88%
Citadel Advisors LLC
3,834,999US$16.1m1.61%0.01%
4.59%
OrbiMed Advisors LLC
3,602,450US$15.2m69.5%0.26%
4.54%
State Street Global Advisors, Inc.
3,568,242US$15.0m11.9%no data
3.83%
Vanguard Capital Management, LLC
3,007,093US$12.7m0%no data
3.52%
Longitude Capital Management Co., LLC
2,765,381US$11.6m0%1.12%
3.5%
Woodline Partners LP
2,750,532US$11.6m-14%0.04%
2.81%
Mizuho Financial Group, Inc.
2,203,631US$9.3m0%0.02%
2.39%
Avoro Capital Advisors LLC
1,875,000US$7.9m-43.2%0.1%
2.14%
Point72 Asset Management, L.P.
1,680,449US$7.1m-11.3%0.01%
2.05%
Millennium Management LLC
1,612,780US$6.8m77.6%no data
2.02%
Balyasny Asset Management L.P.
1,589,585US$6.7m-2.78%0.01%
1.93%
Geode Capital Management, LLC
1,513,777US$6.4m4.7%no data
1.87%
ADAR1 Capital Management, LLC
1,467,350US$6.2m5.33%0.41%
1.81%
The Goldman Sachs Group, Inc.
1,418,916US$6.0m186%no data
1.53%
Nantahala Capital Management, LLC
1,200,000US$5.1m20%0.33%
1.53%
683 Capital Management, LLC
1,200,000US$5.1m7.14%0.47%
1.41%
Dimensional Fund Advisors LP
1,103,584US$4.6m27.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 15:50
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lexeo Therapeutics, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC